These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 3382293

  • 21. Concerns with postmarketing surveillance.
    Norvell MJ, Anderson RJ.
    Am J Hosp Pharm; 1984 Jan; 41(1):54, 56. PubMed ID: 6695933
    [No Abstract] [Full Text] [Related]

  • 22. 'Dear doctor...'--evaluating the impact of risk communication efforts.
    Seligman PJ.
    Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):291-3. PubMed ID: 12812008
    [No Abstract] [Full Text] [Related]

  • 23. The drug safety system conundrum.
    Tiedt TN.
    Food Drug Law J; 2007 Jun; 62(3):547-558. PubMed ID: 17915396
    [No Abstract] [Full Text] [Related]

  • 24. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD, Feigal D.
    Food Drug Law J; 2007 Jun; 62(3):529-46. PubMed ID: 17915395
    [No Abstract] [Full Text] [Related]

  • 25. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK, Swartz L.
    Arch Intern Med; 2005 Jun 27; 165(12):1363-9. PubMed ID: 15983284
    [Abstract] [Full Text] [Related]

  • 26. Improving patient care by reporting problems with medical devices.
    White GG, Weick-Brady MD, Goldman SA, Gross TP, Kennedy DL, Lucas BS, Merritt K, Naschinski C.
    CRNA; 1998 Nov 27; 9(4):139-56. PubMed ID: 9866489
    [Abstract] [Full Text] [Related]

  • 27. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM.
    Pharm Times; 1986 Apr 27; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract] [Full Text] [Related]

  • 28. The pharmacist and adverse drug reaction reporting.
    Pearson K.
    Hosp Pharm; 1982 Aug 27; 17(8):421-2, 427-30. PubMed ID: 10256700
    [Abstract] [Full Text] [Related]

  • 29. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun 03; 58(105):31596-614. PubMed ID: 10171452
    [Abstract] [Full Text] [Related]

  • 30. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S.
    Mod Healthc; 1997 Mar 10; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract] [Full Text] [Related]

  • 31. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 32. Improving how we evaluate the toxicity of approved drugs.
    Reidenberg MM.
    Clin Pharmacol Ther; 2006 Jul 15; 80(1):1-6. PubMed ID: 16815311
    [No Abstract] [Full Text] [Related]

  • 33. Medical device reporting: manufacturer reporting, importer reporting, user facility reporting, distributor reporting. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan 26; 65(17):4112-21. PubMed ID: 11010653
    [Abstract] [Full Text] [Related]

  • 34. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N, Nasar A, Suri MF, Qureshi AI.
    J Clin Neuromuscul Dis; 2009 Sep 26; 11(1):1-6. PubMed ID: 19730016
    [Abstract] [Full Text] [Related]

  • 35. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA, Brushwood DB.
    J Health Law; 2000 Sep 26; 33(3):383-454. PubMed ID: 11184355
    [Abstract] [Full Text] [Related]

  • 36. [Adverse events and adverse reactions associated with drugs--important actual spontaneous reporting of the drug event].
    Homma M.
    Ryumachi; 1992 Oct 26; 32(5):429-31. PubMed ID: 1440077
    [No Abstract] [Full Text] [Related]

  • 37. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA.
    Pharmacoepidemiol Drug Saf; 2002 Sep 26; 11(6):437-8. PubMed ID: 12426926
    [No Abstract] [Full Text] [Related]

  • 38. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K.
    Ann Clin Psychiatry; 2008 Sep 26; 20(1):21-31. PubMed ID: 18297583
    [Abstract] [Full Text] [Related]

  • 39. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA.
    Med Interface; 1996 May 26; 9(5):85-7. PubMed ID: 10157690
    [Abstract] [Full Text] [Related]

  • 40. Adverse drug reaction reporting--proposal to implement a revised system.
    Linkewich JA.
    Hosp Pharm; 1989 Feb 26; 24(2):122-4. PubMed ID: 10292192
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.